Nu-Med Plus, Inc.

OTCPK:NUMD Stock Report

Market Cap: US$793.7k

Nu-Med Plus Valuation

Is NUMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NUMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NUMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NUMD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUMD?

Key metric: As NUMD is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NUMD. This is calculated by dividing NUMD's market cap by their current book value.
What is NUMD's PB Ratio?
PB Ratio-3.9x
Book-US$204.54k
Market CapUS$793.71k

Price to Book Ratio vs Peers

How does NUMD's PB Ratio compare to its peers?

The above table shows the PB ratio for NUMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.3x
DYNT Dynatronics
0.2xn/aUS$1.0m
BRSF Brain Scientific
0.2xn/aUS$932.0k
ESMC Escalon Medical
0.9xn/aUS$964.0k
SONX Sonendo
0.1x21.8%US$1.2m
NUMD Nu-Med Plus
n/an/aUS$793.7k

Price-To-Book vs Peers: NUMD has negative equity and a Price-To-Book Ratio (-3.9x) compared to the peer average (0.4x).

Price to Book Ratio vs Industry

How does NUMD's PB Ratio compare vs other companies in the US Medical Equipment Industry?

26 CompaniesPrice / BookEstimated GrowthMarket Cap
NVRO Nevro
0.5x3.3%US$123.28m
CODX Co-Diagnostics
0.4x-8.3%US$26.50m
RVP Retractable Technologies
0.3xn/aUS$22.15m
HLTH Cue Health
0.06x51.0%US$14.72m
NUMD is unprofitableIndustry Avg. 2.7xNo. of Companies26PB0246810+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NUMD has negative equity and a Price-To-Book Ratio (-3.9x) compared to the US Medical Equipment industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is NUMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-3.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NUMD's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 12:51
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nu-Med Plus, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution